UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 12, 2008
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
TRANSACTION IN OWN SHARES
NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME
On 31 January 2008 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk has repurchased B shares for an amount of DKK 2
billion in the period from 31 January 2008 to 6 August 2008. The programme
thereby ended on 6 August 2008.
Since the announcement as of 4 August 2008, the following transactions have been
made under the programme:
NUMBER OF AVERAGE TRANSACTION
SHARES PURCHASE PRICE VALUE, DKK
ACCUMULATED, LAST
ANNOUNCEMENT 6,095,407 1,932,455,699
4 August 2008 70,000 310.7800 21,754,600
5 August 2008 65,700 310.2920 20,386,184
6 August 2008 80,800 313.9800 25,369,584
ACCUMULATED, 2008 6,311,907 1,999,966,068
With the transactions stated above, Novo Nordisk owns a total of 18,015,430
treasury shares, corresponding to 2.8% of the share capital. The total amount of
shares in the company is 634,000,000 including treasury shares. Novo Nordisk is
a healthcare company and a world leader in diabetes care. In addition, Novo
Nordisk has a leading position within areas such as haemostasis management,
growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in
80 countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com
Company Announcement no 50 / 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: August 12, 2008 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer